News | August 10, 2009

HCSC Expands Pharmacy Adherence Program for Cholesterol-Lowering Drugs

August 10, 2009 – Health Care Service Corp. (HCSC), which operates the Blue Cross and Blue Shield plans in Illinois, New Mexico, Oklahoma and Texas, is expanding a successful new cholesterol medication adherence program that provides physicians with greater insight into their patients’ medication use.

The pharmacy adherence program has proven to increase the use of cholesterol medication by 25 percent for those not following their doctor’s orders, the company said. As the country’s largest customer-owned health insurer with 12.4 million members, HCSC wants the program to serve as a model for the healthcare system.

“By not taking cholesterol medications, many people are subjecting themselves to serious cardiovascular complications that could otherwise be prevented,” says Fawwaz M. Shoukfeh, M.D., a physician in Texas who sees great benefit from the program. “This allows us to better communicate with our patients, improve their health, and ultimately help reduce the cost of their care.”

Originally designed with its pharmacy benefits manager, Prime Therapeutics, the program allows HCSC to analyze pharmaceutical data to identify members not refilling their prescribed cholesterol medications. The company then notifies the patients and their physicians, who also receive a customized patient report that includes lab results, drug quantities filled, dispensed dates and refill due dates. Members of Blue Cross and Blue Shield of Texas have used the program since last year.

“In addition to increasing statin medication use, the program also can save money for our customers and members,” said Kevin Slavik, senior pharmacy director at HCSC. “Through a pharmacy benefit step therapy plan, we are able to encourage the use of generic medications.”

HCSC plans to expand the program to its other Blues plans in Illinois, New Mexico, Oklahoma this month. The program also will soon target diabetes and other conditions.

For more information: www.HCSC.com


Related Content

News | Pharmaceuticals

July 10, 2024 — Reviva Pharmaceuticals Holdings, Inc., a late-stage pharmaceutical company developing therapies that ...

Home July 10, 2024
Home
News | Pharmaceuticals

June 5, 2024 — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data ...

Home June 05, 2024
Home
News | Pharmaceuticals

May 24, 2024 — Lexicon Pharmaceuticals, Inc. announced a new post-hoc analysis of clinical data showing that INPEFA ...

Home May 24, 2024
Home
News | Pharmaceuticals

May 6, 2024 — Tenax Therapeutics, Inc., a Phase 3, development-stage pharmaceutical company focused on identifying ...

Home May 06, 2024
Home
News | Pharmaceuticals

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
News | Pharmaceuticals

January 25, 2024 — Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti ...

Home January 25, 2024
Home
News | Pharmaceuticals

November 21, 2023 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home November 21, 2023
Home
Feature | Pharmaceuticals | By Christine Book

In a new 3-part video series on hypertrophic cardiomyopathy with Christine E. Seidman, MD, FACC, FAHA, Managing Editor ...

Home October 25, 2023
Home
Videos | Pharmaceuticals

In this third and final segment in DAIC’s “One on One” series with Dr. Christine Seidman, learn what’s on the horizon at ...

Home September 26, 2023
Home
Subscribe Now